<DOC>
	<DOC>NCT00487591</DOC>
	<brief_summary>The primary objective of this study is to compare the effect of simvastatin plus Omacor to simvastatin plus placebo for lowering non-high density lipoprotein cholesterol in subjects with mixed dyslipidemia.</brief_summary>
	<brief_title>An Evaluation of Simvastatin Plus Omacor Compared to Simvastatin Plus Placebo in Subjects With Mixed Dyslipidemia</brief_title>
	<detailed_description>This trial will utilize a randomized, double-blind, two-period crossover design. At Visit 4 (Week 0), after a 5-week diet lead-in/baseline period, subjects meeting all entry criteria will be randomized to one of two double-blind treatment sequences, simvastatin/Omacor first or simvastatin/placebo first. Each treatment period consists of 6 weeks. After randomization, subjects will self-administer the study drugs once a day in the evening.</detailed_description>
	<mesh_term>Dyslipidemias</mesh_term>
	<mesh_term>Simvastatin</mesh_term>
	<criteria>Men and women, ages 1879 inclusive Fasting, untreated nonhighdensity lipoprotein cholesterol (nonHDLC level above ATP III goals Fasting, untreated triglyceride (TG) level in the high to very high range Provide written informed consent and authorization for protected health information Pregnancy Use of lipidaltering drugs which cannot be stopped History of certain cardiovascular conditions or cardiac surgery within the prior 6 months Body mass index above 40 kg per square meter Allergy or sensitivity to omega3 fatty acids or to statin drugs Poorlycontrolled conditions including diabetes, hypertension, or thyroid disease Certain muscle, liver, kidney, lung or gastrointestinal conditions Certain medications Active cancers treated within prior 2 years (except nonmelanoma skin cancer)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>April 2008</verification_date>
	<keyword>cholesterol</keyword>
	<keyword>dyslipidemia</keyword>
	<keyword>omega 3</keyword>
</DOC>